Stealth BioTherapeutics (MITO) Reports In-Line Q2 EPS

Stealth BioTherapeutics (NASDAQ: MITO) reported Q2 EPS of ($0.02), in-line with the analyst estimate of ($0.02).

"The clinical efficacy data observed in Barth and other mitochondrial diseases caused by nuclear DNA mutations confirm our confidence in developing elamipretide to treat rare genetic diseases with no approved therapies," said Reenie McCarthy, chief executive officer of Stealth. "We are keenly aware that time is not on the side of patients suffering from these devastating conditions, with recent cardiac-related fatalities of young boys and men in the Barth community underscoring the urgency of effective treatment options. While the FDA that we bolster our clinical evidence package in Barth prior to submission of an NDA, we remain committed to moving as quickly as possible to address this serious unmet need, and accordingly hope to address the FDA's concerns with a proposed post-marketing protocol and potential NDA submission later this year."

For earnings history and earnings-related data on Stealth BioTherapeutics (MITO) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Evogene chairman to address dissident shareholders on results call
• Z Squared outlines AI power strategy and Paradox Data acquisition